USD 3.54 Billion
Global Idiopathic Pulmonary Fibrosis Market Size, Share, Growth Analysis, By Drug Type(Pirfenidone and Nintedanib), By By Distribution Channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2024-2031
Report ID:
SQMIG35H2223 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
61 |
Figures:
75
Global Idiopathic Pulmonary Fibrosis Market Insights
Global Idiopathic Pulmonary Fibrosis Market size was valued at USD 3.54 Billion in 2022 and is poised to grow from USD 3.78 Billion in 2023 to USD 6.45 Billion by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).
Global Idiopathic Pulmonary Fibrosis (IPF) Market continues to witness notable growth and attention due to the increasing prevalence of this debilitating lung disease. Idiopathic pulmonary fibrosis is a chronic and progressive disorder characterized by the scarring of lung tissues, leading to impaired lung function and respiratory difficulties. The market's expansion is fueled by various factors, including advancements in diagnostic technologies that facilitate early detection and diagnosis, leading to better management of the disease. Additionally, the growing awareness among healthcare professionals and patients about the importance of early intervention has contributed to the market's growth. Pharmaceutical companies and researchers have been actively engaged in developing innovative treatment options and therapeutic approaches to address the unmet medical needs of IPF patients. The introduction of novel drugs and therapies, including antifibrotic agents, immunosuppressants, and targeted therapies, has significantly improved patient outcomes and quality of life. However, challenges remain, such as the high cost of treatment, limited access to therapies in certain regions, and the need for further research to unravel the complex mechanisms underlying IPF. To stay up-to-date with the latest developments and trends in the global market, continuous monitoring of new research and regulatory updates is essential.
US Idiopathic Pulmonary Fibrosis Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Nintedanib
Fastest Growth
Nintedanib
Growth Rate
6.9% CAGR
Global Idiopathic Pulmonary Fibrosis Market ($ Bn)
Country Share for North America Region (%)
Global Idiopathic Pulmonary Fibrosis Market By Type ($ Bn)
Global Idiopathic Pulmonary Fibrosis Market By Type (%)
To get more reports on the above market click here to Buy The Report
Global Idiopathic Pulmonary Fibrosis Market Segmental Analysis
Global Idiopathic Pulmonary Fibrosis Market is segmented on the basis of By Drug Type
By Distribution Channel, and region. Based on Drug Type, the market can be segmented into Pirfenidone & Nintedanib. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Providers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Idiopathic Pulmonary Fibrosis Market Analysis By Drug Type
Nintedanib emerges as the dominant segment in the Global Idiopathic Pulmonary Fibrosis (IPF) Market. Nintedanib is an antifibrotic agent that has gained widespread acceptance among healthcare professionals and patients alike. Its efficacy in slowing down the progression of IPF and improving lung function has contributed to its market dominance. Pharmaceutical companies' continued focus on research and development, along with regulatory approvals and market penetration, have propelled Nintedanib's position as the leading therapeutic option for managing idiopathic pulmonary fibrosis.
In recent years, the fastest-growing segment in the Global Idiopathic Pulmonary Fibrosis (IPF) Market has been Pirfenidone. Pirfenidone is another antifibrotic agent that has gained significant traction due to its ability to reduce lung scarring and preserve lung function in IPF patients. Its popularity has surged owing to positive clinical outcomes and a growing body of evidence supporting its efficacy. The rapid expansion of the Pirfenidone market is also driven by increased adoption in emerging economies, rising awareness about IPF, and expanding patient access to the drug through healthcare initiatives and reimbursement policies. As a result, Pirfenidone is witnessing robust growth and is expected to continue its upward trajectory in the coming years.
Idiopathic Pulmonary Fibrosis Market Analysis By Distribution Channel
The Hospitals and Clinics segment emerges as the dominant application category in the Global Idiopathic Pulmonary Fibrosis (IPF) Market. Hospitals and clinics play a crucial role in providing comprehensive medical care to IPF patients, offering specialized diagnostic services, treatment options, and multidisciplinary care teams. The prominence of this segment can be attributed to the high patient footfall in healthcare facilities for IPF management, especially in severe cases that require continuous monitoring and advanced medical interventions. Moreover, hospitals and clinics often serve as referral centers, ensuring that a significant proportion of IPF patients seek medical attention and treatment in these settings.
The Pharmacies segment is experiencing the fastest growth in the Global Idiopathic Pulmonary Fibrosis (IPF) Market. This growth is driven by factors such as increased patient awareness about IPF and its available treatment options, resulting in higher demand for medications like Nintedanib and Pirfenidone, the two dominant drugs for IPF. Additionally, the growing emphasis on early detection and diagnosis of IPF in outpatient settings has led to more prescriptions being dispensed through pharmacies. As a result, pharmacies have become essential points of access for IPF medications, making this segment the fastest growing due to the rising number of diagnosed cases and improved treatment rates.
Global Idiopathic Pulmonary Fibrosis Market By Type, 2023 (%)
To get detailed analysis on other segments, Request For Free Sample Report
Global Idiopathic Pulmonary Fibrosis Market Regional Insights
North America dominated the Global Idiopathic Pulmonary Fibrosis (IPF) Market. The region's leading position can be attributed to well-established healthcare infrastructure, high awareness about IPF among healthcare professionals and patients, and a strong focus on research and development. North America is home to several key pharmaceutical companies actively involved in developing and marketing IPF therapies. Additionally, favorable reimbursement policies and early adoption of novel treatments contribute to the region's dominance in the IPF market.
Asia Pacific is experiencing the fastest growth in the Global Idiopathic Pulmonary Fibrosis (IPF) Market. The region's rapid economic development, increasing healthcare spending, and a growing geriatric population are key drivers of this growth. Moreover, rising awareness about IPF and improvements in healthcare access and facilities are leading to earlier diagnosis and better disease management. Pharmaceutical companies are also targeting the Asia Pacific market, launching their IPF medications in various countries within the region. These factors collectively contribute to Asia Pacific's remarkable growth as the fastest-growing segment in the IPF market.
Global Idiopathic Pulmonary Fibrosis Market By Geography, 2024-2031
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Global Idiopathic Pulmonary Fibrosis Market Dynamics
Idiopathic Pulmonary Fibrosis Market Drivers
Continuous advancement in medical research and drug development
- A key driver of the Global Idiopathic Pulmonary Fibrosis (IPF) Market is the continuous advancement in medical research and drug development. The ongoing efforts to understand the underlying mechanisms of IPF and develop innovative therapies have resulted in the introduction of new treatment options, such as antifibrotic agents like Nintedanib and Pirfenidone. These advancements have significantly improved patient outcomes and quality of life, driving the growth of the market.
Idiopathic Pulmonary Fibrosis Market Restraints
High cost of treatment
- One key restraint in the Global Idiopathic Pulmonary Fibrosis (IPF) Market is the high cost of treatment. The medications used to manage IPF, such as Nintedanib and Pirfenidone, can be expensive, making them less accessible to certain patient populations, especially in lower-income regions. The high cost of treatment can create financial barriers for patients seeking optimal care, impacting treatment adherence and overall disease management. Additionally, this cost constraint can pose challenges to healthcare systems and lead to concerns about equitable access to effective therapies for all IPF patients.
Request Free Customization of this report to help us to meet your business objectives.
Global Idiopathic Pulmonary Fibrosis Market Competitive Landscape
The competitive landscape of the Global Idiopathic Pulmonary Fibrosis (IPF) Market is characterized by intense research and development activities focused on developing innovative treatment options and improving patient outcomes. Pharmaceutical companies are actively engaged in introducing antifibrotic agents and targeted therapies to address the unmet medical needs of IPF patients. Additionally, healthcare providers and research institutions play a crucial role in advancing diagnostic techniques and patient care, while advocacy groups and patient organizations contribute to raising awareness about IPF and its management. The market's competitiveness is further driven by regulatory approvals, market penetration strategies, and efforts to enhance healthcare infrastructure and access to IPF treatments globally.
Idiopathic Pulmonary Fibrosis Market Top Player’s Company Profiles
- FibroGen, Inc. (US)
- Horizon Therapeutics plc (Ireland)
- AstraZeneca (UK)
- Novartis AG (Switzerland)
- GlaxoSmithKline plc (UK)
- Genentech, Inc. (US)
- Bristol Myers Squibb (US)
- Biogen Inc. (US)
- Actelion Pharmaceuticals Ltd. (Switzerland)
- Pfizer Inc. (US)
- Johnson & Johnson (US)
- Sanofi (France)
- Merck & Co., Inc. (US)
- Gilead Sciences, Inc. (US)
- AbbVie Inc. (US)
- Bayer AG (Germany)
- Amgen Inc. (US)
Idiopathic Pulmonary Fibrosis Market Recent Developments
- In January 2023, Daewoong Pharmaceutical and CS Pharmaceuticals entered into an agreement concerning the exclusive rights for the novel PRS inhibitor, Bersiporocin, in Greater China, encompassing mainland China, Hong Kong, Taiwan, and Macau. The deal involves CSP obtaining a license for Bersiporocin's use in treating idiopathic pulmonary fibrosis (IPF) and potentially other fibrotic conditions, with a total value of up to USD 336 million. This includes an upfront payment and development milestone amounts of up to USD 76 million, as well as double-digit royalties on net sales.
- In May 2022, Sandoz introduced a generic version of pirfenidone, which is designated as an AB-rated fully substitutable equivalent to Genentech's Esbriet, in the United States. The launch aims to provide patients with idiopathic pulmonary fibrosis (IPF) in the US with a more affordable treatment option.
Global Idiopathic Pulmonary Fibrosis Key Market Trends
- Increasing focus on the development of targeted therapies: One key market trend in the Global Idiopathic Pulmonary Fibrosis (IPF) market is the increasing focus on the development of targeted therapies. Pharmaceutical companies and researchers are actively exploring and investing in innovative treatment approaches that specifically target the underlying mechanisms and pathways responsible for IPF. This trend aims to offer more effective and personalized treatment options, potentially leading to improved patient outcomes and better disease management. Targeted therapies hold promise in addressing the complex nature of IPF and may pave the way for more tailored and precise treatments in the future.
Global Idiopathic Pulmonary Fibrosis Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our Global Idiopathic Pulmonary Fibrosis Market analysis, the market is witnessing significant growth and attention due to the increasing prevalence of this debilitating lung disease. IPF is characterized by the scarring of lung tissues, leading to impaired lung function and breathing difficulties. The market expansion is driven by factors such as advancements in diagnostic technologies, rising awareness among healthcare professionals and patients, and the development of innovative treatment options, including antifibrotic agents and targeted therapies. North America dominates the market, owing to well-established healthcare infrastructure and a strong focus on research and development. However, the high cost of treatment remains a key restraint, creating financial barriers for patients seeking optimal care. Nevertheless, the market shows a promising trend towards the development of targeted therapies, potentially offering more effective and personalized treatment options for IPF patients in the future.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 3.54 Billion |
| Market size value in 2031 | USD 6.45 Billion |
| Growth Rate | 6.9% |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Global Idiopathic Pulmonary Fibrosis Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Global Idiopathic Pulmonary Fibrosis Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Global Idiopathic Pulmonary Fibrosis Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Idiopathic Pulmonary Fibrosis Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Idiopathic Pulmonary Fibrosis Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Idiopathic Pulmonary Fibrosis Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Global Idiopathic Pulmonary Fibrosis Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 617-230-0741
